Korean J Dermatol.  2019 Jan;57(1):9-14.

Efficacy and Safety of Secukinumab for the Treatment of Moderate to Severe Psoriasis in Korea

• Ha DL
• Kim WI
• Yang MY
• Lee WK
• Kim T
• Park S
• Lee HJ
• Kim GW
• Kim HS
• Ko HC
• Kim MB
• Kim BS

Abstract

BACKGROUND
Secukinumab, a fully human monoclonal antibody that targets interleukin (IL)-17A, which is a central cytokine in the pathogenesis of psoriasis, has emerged as a promising treatment for moderate to severe psoriasis. However, to date, there are no real-world data for secukinumab in Korean patients with psoriasis.
OBJECTIVE
To assess the clinical efficacy and safety of secukinumab in Korean patients with psoriasis.
METHODS
Prospective data were gathered during follow-up from 28 consecutive patients with chronic plaque-type psoriasis treated with secukinumab for minimum of 12 weeks at a single referral center. Patient demographics, Psoriasis Area Severity Index (PASI) score, Physicians' Global Assessment (PGA), Dermatologic Life Quality Index (DLQI), and adverse events were investigated.
RESULTS
The mean PASI score was significantly decreased after the induction period of secukinumab treatment (paired t-test, p<0.05). Of the 28 patients, 17 (60.7%) had obtained near complete clearance (PASI 90) at the last follow-up visit. No unexpected adverse events, other than nasopharyngitis, were observed.
CONCLUSION
Secukinumab can be of benefit for the treatment of Korean patients with psoriasis, as the treatment was associated with a rapid and satisfactory response and safety profile.

Keyword

Clinical setting; Efficacy; Psoriasis; Safety; Secukinumab

MeSH Terms

Demography
Follow-Up Studies
Humans
Interleukins
Korea*
Nasopharyngitis
Prospective Studies
Psoriasis*
Quality of Life
Referral and Consultation
Treatment Outcome
Interleukins